Lung Cancers Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

Also known as: LUng Cancer / Cancer, Lung / Lung neoplasm malignant / Lung cancer NOS / Cancer of lung / Ca lung

IndicationStatusPhase
DBCOND0072929 (Lung Cancers)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02414269Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen MesothelinTreatment
NCT03220477Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.Treatment
NCT02402920Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung CancerTreatment